만성 C형간염 환자에서 Pegylated Interferon α-2a 치료 중 발생한 폐독성 1예
Pulmonary Toxicity by Pegylated Interferon α-2a in a Patient with Chronic Hepatitis C
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
인터페론 알파 (IFN α)는 여러 바이러스의 세포 내 복제를 억제하는 당단백질(glycoprotein)로 만성 C형간염 치료의 기본이 되었고, 그 동안 인터페론 치료와 연관된 여러 가지 부작용이 보고되었다.인터페론의 흔한 부작용으로 전신쇠약, 발열, 관절통, 두통과 같은 독감 유사(flu-like) 증세, 백혈구감소증, 그리고 혈소판감소증 등이 있고,1 자가면역질환, 심장독성의 발생과 악화, 심지어 급사가 중대한 부작용으로 알려졌다.2,3 그러나 IFN α 단독치료나 IFN α/ribavirin 병합치료 후 발생한 폐독성 합병증은 상대적으로 매우 드물게 보고되었다.4-6 저자들은 만성 C형간염 환자에서 PEG-IFN α-2a (Pegasys, Hoffmann-LaRoche Corp.)로 치료 중 발생한 폐독성 1예를 경험하였다.
Abstract
The combination therapy with pegylated interferon α and ribavirin has increasingly prescribed for chronic hepatitis C. Although many side effects of interferon such as flu-like symptoms, gastrointestinal and neuropsychiatric symptoms are well known, only several cases of interferon-induced pulmonary toxicity have been reported. Interferon-induced pulmonary toxicity usually develops from 2 weeks to 12 weeks after treatment for HCV infection. Diagnosis is commonly based on clinical findings such as a dry cough, dyspnea, hypoxemia, and a restrictive pattern in pulmonary function testing, bilateral diffuse parenchymal infiltrations, histopathological findings of interstitial pneumonitis, and exclusion of any other causative agents. Prompt withdrawal of the drug is the cornerstone of treatment. We report a case of PEG-IFN α-2a induced pulmonary toxicity in a 50-year-old male patient with hepatitis C. To our knowledge, this is the first case of pegylated interferon α-2a induced pulmonary toxicity in Korea.
참고문헌 (11)
- Okanoue T, "Side effect of high-dose interferon therapy for chronic hepatitis C", 25, pp.283~291 (1996)
- Sonnenblick M, "Cardiotoxicity of interferon:A review of 44 cases", 99, pp.557~561 (1991)
- Conlon KC, "Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy", 65, pp.2237~2242 (1990)
- Chin K, "Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C", 105, pp.939~941 (1994)
- Abi-Nassif S, "Pegylated interferon and ribavirin induced interstitial pneumonitis with ARDS", 124, pp.406~410 (2003)
- Fuhrmann V, "Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection", 49, pp.1966~1970 (2004)
- Jeong HS, "A case of interstitial pneumonitis after interferon therapy for chronic hepatitis C", 34, pp.698~703 (1999)
- Karim A, "Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection", 322, pp.233~235 (2001)
- Abbas AK, "Effector mechanism of immune responses. In: Cellular and molecular Immunology.", pp.235~335 (2000), Philadelphia: WB Saunders
- Dusheiko G, "Ribavirin treatment for patients with chronic hepatitis C: result of a placebo-controlled study", 25, pp.591~598 (1996)
- Jeong HS, "A case of interstitial pneumonitis after interferon therapy for chronic hepatitis C", 34, pp.698~703 (1999)